Correction: PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: a multiomics analysis

Related Posts

• Correction: PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: a multiomics analysis

• BET Inhibitor BMS‑986158 for MF: Phase I/II Trial Results

  KEY TAKEAWAYS The phase I/II trial aimed to evaluate the efficacy and safety of BMS-986158,…

• Phase II Trial of SAR439859 Against Endocrine Monotherapy in Pre-and Post-Menopausal

  KEY TAKEAWAYS The phase II ACT16105 study aimed to assess the safety and effectiveness of…